DxS Grants DuPont Qualicon License to Scorpions Technology for Food and Beverage Diagnostics

WILMINGTON, Del., — DxS Ltd, a personalized medicine company, has granted DuPont Qualicon a license to use its novel Scorpions diagnostic platform to develop tests for use by the food industry.

Financial terms were not disclosed.

The deal will allow DuPont Qualicon to use DxS Scorpions technology, a highly sensitive and adaptable platform, to develop rapid multiplex assays for detecting microorganisms that affect food safety and quality. Scorpions is a homogeneous, closed-tube platform for PCR analysis for which DxS own the worldwide IP. The technology provides an accurate, rapid and reliable fluorescence-based signal generation system with application rights in in vitro diagnostics, genetic analysis, biothreat detection, environmental utility and now also food and drink microbial testing, the company said.

“With Scorpions cutting-edge technology, we can develop increasingly faster, more sensitive tests for pathogens and spoilage organisms that anticipate and satisfy the evolving needs of the food industry for safer, higher quality products,” said Kevin Huttman, president, DuPont Qualicon.

“Scorpions has unparalleled sensitivity and specificity making it ideal for detecting often difficult-to-find organisms which may not be identifiable through other diagnostic platforms,” said Stephen Little, CEO of DxS.